Prescription medication · Partial Opioid Agonist

buprenorphine

Also sold as Subutex, Sublocade. This medicine treats opioid dependence.

Data updated 2026-05-15

90,121
FDA reportsOften reported
29
InteractionsSeveral interactions
1
Recall record

What the data shows

buprenorphine (Subutex) is a prescription Partial Opioid Agonist, more reported than most tracked drugs (90,121 FDA reports), with 29 documented drug interactions.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

buprenorphine (Subutex) is a prescription Partial Opioid Agonist. This medicine treats opioid dependence.

Buprenorphine sublingual tablets help treat opioid dependence. It should be part of a full treatment plan with counseling and support.

Drug Pricing (NADAC)

Generic Price

$28.84/unit

Generic Available

Yes (32 manufacturers)

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

NADAC price trail: BUPRENORPHINE 10 MCG/HR PATCH

Same CMS presentation as the headline generic unit price above (2 effective dates). Adjacent % compares consecutive NADAC releases for this description only, not a patient out-of-pocket quote. Latest step: +2.5% vs prior release.

Effective NADAC / unit vs prior NDCs
July 17, 2024 $28.13/EA - 1
December 18, 2024 $28.84/EA +2.5% 7
View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

This medicine treats opioid dependence.

Common side effects

Headache, Nausea, Vomiting

Key warnings

Buprenorphine can be abused, like other opioids.

The sections below are summarized in plain English from buprenorphine's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Buprenorphine is a partial opioid agonist. This means it binds to the same receptors in the brain as opioids, but it does not activate them as strongly. This helps to reduce cravings and withdrawal symptoms without causing the same high as other opioids.

Side Effects (from patient reports)

Based on 90,121 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for buprenorphine, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for buprenorphine each year to the FDA Adverse Event Reporting System (FAERS).

05,00010,00015,00020,00025,000 20042007201020132016201920222025 4,608

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where buprenorphine sits

buprenorphine has more FDA adverse-event reports than 84% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is buprenorphine; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 90,121 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2004–2025.

Total Reports

90,121

Reports Mentioning Death

25,836

28.7% of reports — not proof of cause

Hospitalization Reports

10,461

Top Indication

Product Used For Unknown Indication

Gender Distribution

Female 35,467 (56%)
Male 27,246 (43%)

Age Distribution

0–17 472
18–44 9,031
45–64 6,943
65–74 2,313
75+ 2,795

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 DEATH 13,278
2 DRUG DEPENDENCE 12,452
3 OVERDOSE 10,911
4 TOXICITY TO VARIOUS AGENTS 10,722
5 PAIN 8,157
6 DRUG WITHDRAWAL SYNDROME 6,860
8 EMOTIONAL DISTRESS 5,436
9 NAUSEA 4,411
10 DRUG ABUSE 3,622
11 PRODUCT ADHESION ISSUE 3,292
12 APPLICATION SITE RASH 3,042
13 INADEQUATE ANALGESIA 3,028
14 DIZZINESS 2,578
15 RASH 2,501
16 APPLICATION SITE PRURITUS 2,341

Reactions in Death Reports

DEATH 13,268
TOXICITY TO VARIOUS AGENTS 8,899
OVERDOSE 6,404
DRUG ABUSE 1,762
DRUG DEPENDENCE 1,610
ACCIDENTAL OVERDOSE 791
ARTHRALGIA 772
ASTHENIA 759
DIZZINESS 708
PAIN 694

Reactions in Hospitalization Reports

TOXICITY TO VARIOUS AGENTS 1,763
DRUG ABUSE 1,069
PAIN 978
CONFUSIONAL STATE 907
OVERDOSE 861
DRUG DEPENDENCE 833
NAUSEA 825
VOMITING 824
FATIGUE 769
CONDITION AGGRAVATED 738

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Buprenorphine can be abused, like other opioids. Taking buprenorphine with benzodiazepines or other depressants can cause serious breathing problems, coma, or death. Keep this medicine out of the reach of children, as it can cause severe breathing problems and death. Using opioids for a long time during pregnancy can cause withdrawal symptoms in the newborn.

Known Drug Interactions

moderate oxycodone

Intervention: Avoid concomitant use Examples: Butorphanol, nalbuphine, pentazocine, buprenorphine Muscle Relaxants Clinical Impact: Oxycodone may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.

Mechanism: Oxycodone can make the muscle-weakening effects of other drugs stronger and can cause your breathing to slow down significantly. This combination can be very dangerous for your lungs and muscles.

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Mechanism: Both of these medications increase the amount of a brain chemical called serotonin. Taking them at the same time can cause serotonin levels to become dangerously high.

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Mechanism: Both drugs increase serotonin levels in the brain, which can cause a serious and potentially dangerous reaction.

Examples: Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), certain muscle relaxants (i.e., cyclobenzaprine, metaxalone), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).

Mechanism: These medications both affect the serotonin system, and taking them together can lead to a dangerous buildup of this chemical in your body.

ketoconazole), protease inhibitors (e.g., ritonavir) CYP3A4 Inducers Clinical Impact: The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see Clinical Pharmacology (12.3)] , potentially resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to buprenorphine.

Mechanism: Ketoconazole interferes with the enzymes that break down buprenorphine, which can change the amount of medicine that stays in your blood.

Check all your medications →

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

Can I cut or chew the tablet?
No, you must not cut, chew, or swallow the buprenorphine sublingual tablet. Place it under your tongue and let it dissolve completely.
What should I do if I feel sick after taking this medicine?
Tell your doctor if you feel sick, nauseous, or vomit after taking buprenorphine.
Can I drink alcohol while taking this medicine?
No, do not drink alcohol while taking buprenorphine. It can cause serious side effects, including breathing problems.
What if I accidentally give this medicine to my child?
Seek immediate medical attention if a child takes this medicine. It can cause severe, possibly fatal, breathing problems.
Can I take other medications with buprenorphine?
Talk to your doctor about all the medicines you take, including over-the-counter drugs and supplements. Some medicines can interact with buprenorphine.
How often will I see my doctor while taking this medicine?
Your doctor will determine how often you need to be seen. Follow their instructions carefully.
What are the signs of an overdose?
Signs of an overdose include slow or shallow breathing, extreme sleepiness, and unresponsiveness. Seek immediate medical attention if you suspect an overdose.
Can I stop taking this medicine suddenly?
No, do not stop taking this medicine suddenly. Your doctor will slowly lower your dose to prevent withdrawal symptoms.
What is naloxone and why might I need it?
Naloxone is a medicine that can reverse an opioid overdose. Your doctor may prescribe it for you in case of an emergency.
What should I do if I am going to have surgery?
Tell your doctor that you are taking buprenorphine before any surgery or medical procedure.
What are the common side effects of buprenorphine?
The registry lists Headache, Nausea, Vomiting, Sweating, Constipation among the most-reported FAERS reaction terms for buprenorphine. The compiled record contains 90,121 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does buprenorphine interact with other medications?
The registry has 29 documented interaction rows for buprenorphine. Notable source-record pairings include oxycodone, trazodone, cyclobenzaprine. These rows are not a complete medication review.
What drug class is buprenorphine?
buprenorphine belongs to the Partial Opioid Agonist drug class. It requires a prescription (Rx). This medicine treats opioid dependence.
What pregnancy or breastfeeding source fields are listed for buprenorphine?
The FDA label for buprenorphine contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.
Has buprenorphine been recalled?
There is 1 recall associated with buprenorphine products. Crystallization; identified as Buprenorphine free base. Check the recalls section below for full details and affected products.

Active Recalls

Class II March 13, 2026

Crystallization; identified as Buprenorphine free base

ENDO USA, Inc.

Other drugs grouped near buprenorphine - same-class peers and common alternatives.

Compare buprenorphine vs acamprosate side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for buprenorphine: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on buprenorphine

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for buprenorphine

The FDA label for buprenorphine (sold under brand names such as Subutex, Sublocade) classifies it as a prescription-only medication in the Partial Opioid Agonist class. This medicine treats opioid dependence. Official labeling lists 11 commonly reported side effects, including Headache, Nausea, Vomiting.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 90,121 voluntary reports. The database also lists 29 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $28.84.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history (currently 1 recall record on file), and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: February 3, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page